

# Surgical Treatment for Ischaemic Heart Failure Trial (STICH)

<b>Submission date</b> 07/07/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 07/07/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 17/07/2014	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mr Mike Lammiman

**Contact details**  
Department of Cardiology  
Castle Road  
Cottingham  
United Kingdom  
HU16 5JQ  
mike.lammiman@hey.nhs.uk

## Additional identifiers

**ClinicalTrials.gov (NCT)**  
NCT00023595

**Protocol serial number**  
5148

## Study information

**Scientific Title**

Surgical Treatment for Ischaemic Heart Failure Trial (STICH): a multicentre randomised interventional treatment trial

### **Study objectives**

No randomised trial has ever directly compared long-term benefits of surgical and medical treatment of patients with ischaemic heart failure (HF). Along the broad spectrum of severity of ischaemic HF, specific clinical information, such as severe angina or left main coronary artery stenosis, may clearly indicate the need for surgical therapy for some patients.

However, a large number of patients fall into a gray zone without clear evidence for benefit from either medical or surgical therapy. For these patients, evidence supporting choice between therapies was never strong and has only been confused by recent studies showing improved outcomes with both therapies.

Patients for whom equipoise of anticipated benefit now exists between modern medical and surgical therapy represent the broad population who are appropriate candidates for a randomised trial to provide the context for assessing the value of two therapeutic strategies:

1. Medication (MED) alone
2. MED and coronary artery bypass grafting (CABG)

The study is also being run in the USA and includes surgical ventricular reconstruction as a treatment option in those sites only.

As of 13/07/2010 the study is seeking a protocol amendment to extend follow-up for another 9 years.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Hull and East Riding REC, 04/08/2005, ref: 05/MRE00/51

### **Study design**

Multicentre randomised interventional treatment trial

### **Primary study design**

Interventional

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Topic: Cardiovascular; Subtopic: Cardiovascular (all Subtopics); Disease: Cardiovascular

### **Interventions**

1. Optimal medication (for heart failure according to National Institute for Clinical Excellence [NICE] guidelines)
2. CABG and optimal medication

Total duration of treatment: up to 6 years maximum  
Follow-up length: 36 months

### **Intervention Type**

Other

### **Phase**

Not Applicable

### **Primary outcome(s)**

CABG combined with MED compared to MED alone, measured up to 6 years.

### **Key secondary outcome(s)**

Measured up to 6 years:

1. Cardiac magnetic resonance (CMR) of left ventricle (LV) shape, size and function for predicting the benefit of a specific treatment strategy
2. Nuclear cardiology and/or echocardiography testing of myocardial ischaemia

### **Completion date**

30/05/2007

## **Eligibility**

### **Key inclusion criteria**

1. Men
2. Women who are not of childbearing potential
3. Aged 18 years or above
4. Who have a left ventricular ejection fraction (LVEF) less than 0.35 measured by cardiac magnetic resonance (CMR) ventriculogram, gated single photon emission computed tomography (SPECT) ventriculogram, echocardiography, or contrast ventriculogram within three months of trial entry
5. Who have coronary artery disease suitable for revascularisation

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Lower age limit**

18 years

### **Sex**

All

### **Key exclusion criteria**

1. Failure to provide informed consent
2. Aortic valvular heart disease clearly indicating the need for aortic valve repair or replacement
3. Cardiogenic shock (within 72 hours of randomization) as defined by the need for intra-aortic balloon support or the requirement for intravenous inotropic support
4. Plan for percutaneous intervention of coronary artery disease
5. Recent acute myocardial infarction judged to be an important cause of left ventricular dysfunction
6. History of more than one prior coronary bypass operation
7. Non-cardiac illness with a life expectancy of less than 3 years
8. Non-cardiac illness imposing substantial operative mortality
9. Conditions/circumstances likely to lead to poor treatment adherence (e.g., history of poor compliance, alcohol or drug dependency, psychiatric illness, no fixed abode)
10. Previous heart, kidney, liver, or lung transplantation
11. Current participation in another clinical trial in which a patient is taking an investigational drug or receiving an investigational medical device

**MED Therapy Eligibility Criteria:**

12. Absence of left main coronary artery disease as defined by an intraluminal stenosis of 50% or greater
13. Absence of Canadian Class III angina or greater (angina markedly limiting ordinary activity)

**Date of first enrolment**

22/12/2005

**Date of final enrolment**

30/05/2007

## **Locations**

**Countries of recruitment**

United Kingdom

England

United States of America

**Study participating centre**

**Department of Cardiology**

Cottingham

United Kingdom

HU16 5JQ

## **Sponsor information**

**Organisation**

Duke University (USA)

ROR

<https://ror.org/00py81415>

## Funder(s)

### Funder type

Government

### Funder Name

National Institute for Health Research (NIHR) (UK)

### Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

United Kingdom

### Funder Name

National Institutes of Health (NIH) (USA) - National Heart, Blood and Lung Institute (ref: 5 U01 HL069015-4)

## Results and Publications

### Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	23/04/2009		Yes	No
<a href="#">Results article</a>	results	01/05/2009		Yes	No
	results				

<a href="#">Results article</a>		03/08/2010		Yes	No
<a href="#">Results article</a>	results	03/08/2010		Yes	No
<a href="#">Results article</a>	results	28/04/2011		Yes	No
<a href="#">Results article</a>	results	28/04/2011		Yes	No
<a href="#">Results article</a>	results	01/03/2012		Yes	No
<a href="#">Results article</a>	results	29/05/2012		Yes	No
<a href="#">Results article</a>	results	01/01/2013		Yes	No
<a href="#">Results article</a>	results	01/05/2013		Yes	No
<a href="#">Results article</a>	results	07/05/2013		Yes	No
<a href="#">Results article</a>	results	01/10/2013		Yes	No
<a href="#">Results article</a>	results	01/10/2013		Yes	No
<a href="#">Results article</a>	results	01/11/2013		Yes	No
<a href="#">Results article</a>	results	01/12/2013		Yes	No
<a href="#">Results article</a>	results	01/08/2014		Yes	No
<a href="#">Protocol article</a>	protocol	01/12/2007		Yes	No
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes